Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00952380 · ClinicalTrials.gov registry record · Phase 2
Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT00952380 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 38 participants.
The verdict
NCT00952380, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
Three month treatment of acute VTE with Fragmin in pediatric cancer patients
Interventions
- DRUG dalteparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2009-08 |
| Est. Completion | 2018-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00952380
The ClinicalTrials.gov registry entry for NCT00952380 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which dalteparin is the first listed.
NCT00952380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00952380 about?
NCT00952380 is a clinical study titled "Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients". Three month treatment of acute VTE with Fragmin in pediatric cancer patients
What is the current status of trial NCT00952380?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2009-08. Estimated completion is 2018-03.
What interventions are being tested in trial NCT00952380?
The interventions under investigation include: dalteparin (DRUG).
Who is sponsoring clinical trial NCT00952380?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.